(Astegolimab)Biosimilar Reference Antibody-GS40041 新品

货号：GS40041

Astegolimab is a humanized IgG2 monoclonal antibody designed as a specific inhibitor of the interleukin-33 receptor (ST2). It functions by selectively binding to the ST2 subunit (IL1RL1), thereby blocking the binding of its cytokine ligand, interleukin-33 (IL-33). This blockade prevents IL-33/ST2 signaling, a key pathway in type 2 and epithelial-derived inflammation. Astegolimab is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma, with Phase II trials demonstrating positive results in reducing exacerbations in COPD patients with a history of exacerbations.